Trevi Therapeutics advances IPF treatment pipeline with FDA approval. The biopharmaceutical company announced plans for two pivotal phase III trials targeting chronic cough in idiopathic pulmonary fibrosis patients, following positive CORAL trial data in 2025. CEO Jennifer Good highlighted the milestone as a major inflection point for company growth. The FDA alignment represents a critical validation of the therapeutic approach and clears the pathway toward potential commercialization. Investors are watching closely as these trials progress, given the significant unmet medical need in the IPF population. Stock performance will likely depend on trial outcomes and enrollment timelines over the coming months.
Post from MarketNews_en
Log in to interact with content.